These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33953675)

  • 21. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
    Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
    Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations.
    Bailleul Q; Navarin P; Arcicasa M; Bal-Mahieu C; Carcaboso AM; Le Bourhis X; Furlan A; Meignan S; Leblond P
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
    Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
    Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
    Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
    Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Hunter FW; Wouters BG; Wilson WR
    Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
    Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
    Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
    Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
    Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
    Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tirapazamine-embedded polyplatinum(iv) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy.
    Guo D; Xu S; Yasen W; Zhang C; Shen J; Huang Y; Chen D; Zhu X
    Biomater Sci; 2020 Jan; 8(2):694-701. PubMed ID: 31777870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.
    Dragovich PS; Broccatelli F; Chen J; Fan P; Le H; Mao W; Pillow TH; Polson AG; Wai J; Xu Z; Yao H; Zhang D
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5300-5304. PubMed ID: 29079474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity.
    Zhang Z; Tanabe K; Hatta H; Nishimoto S
    Org Biomol Chem; 2005 May; 3(10):1905-10. PubMed ID: 15889173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.